In a recent update, Scotiabank analyst Sung Ji Nam has maintained a "Sector Outperform" rating for Bio-Techne (TECH, Financial). Despite the unchanged rating, the target price for the stock has been adjusted. The new price target is set at $75.00, down from a previous target of $90.00. This adjustment represents a 16.67% decrease from the prior target.
The decision to lower the price target while maintaining the "Sector Outperform" rating reflects the current market conditions and company performance expectations. Investors keen on Bio-Techne (TECH, Financial) should note these updated figures when considering their investment positions.
As of July 11, 2025, these updates are the latest insights provided by Scotiabank, aiming to guide shareholders and potential investors in making informed decisions regarding Bio-Techne (TECH, Financial).
Wall Street Analysts Forecast
Based on the one-year price targets offered by 14 analysts, the average target price for Bio-Techne Corp (TECH, Financial) is $67.33 with a high estimate of $90.00 and a low estimate of $51.00. The average target implies an upside of 24.97% from the current price of $53.88. More detailed estimate data can be found on the Bio-Techne Corp (TECH) Forecast page.
Based on the consensus recommendation from 18 brokerage firms, Bio-Techne Corp's (TECH, Financial) average brokerage recommendation is currently 2.2, indicating "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
Based on GuruFocus estimates, the estimated GF Value for Bio-Techne Corp (TECH, Financial) in one year is $86.06, suggesting a upside of 59.73% from the current price of $53.88. GF Value is GuruFocus' estimate of the fair value that the stock should be traded at. It is calculated based on the historical multiples the stock has traded at previously, as well as past business growth and the future estimates of the business' performance. More detailed data can be found on the Bio-Techne Corp (TECH) Summary page.
